Webinar

LifeSci Talks COA Series | Meaningful Patient Involvement in HTA Decision-making: Where do we go from here?

DateOct 07, 2025

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Alice Biggane, Outcomes Innovation and Research Lead at Pfizer, to discuss how PRO measures inform and impact endpoint adjudication and reimbursement decisions, due to the lack of HRQoL data included. Together they unpack other methods that can be used for augmenting the quantification with regards to HRQoL, and the complex interplay between more general Measures and more sophisticated Instruments and how what that means for HTA Markets. Tune in to learn how leading organizations are working to build more inclusive, efficient, and patient-focused clinical trials.